Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction

James L. Januzzi, Tariq Ahmad, Hillary Mulder, Adrian Coles, Kevin J. Anstrom, Kirkwood F. Adams, Justin A. Ezekowitz, Mona Fiuzat, Nancy Houston-Miller, Daniel B. Mark, Ileana L. Pina, Gayle Passmore, David J. Whellan, Lawton S. Cooper, Eric S. Leifer, Patrice Desvigne-Nickens, G. Michael Felker, Christopher M. O'Connor

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial demonstrated that a strategy to “guide” application of guideline-directed medical therapy (GDMT) by reducing amino-terminal pro–B-type natriuretic peptide (NT-proBNP) was not superior to GDMT alone. Objectives: The purpose of this study was to examine the prognostic meaning of NT-proBNP changes following heart failure (HF) therapy intensification relative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT trial. Methods: A total of 638 study participants were included who were alive and had available NT-proBNP results 90 days after randomization. Rates of subsequent cardiovascular (CV) death/HF hospitalization or all-cause mortality during follow-up and Kansas City Cardiomyopathy Questionnaire (KCCQ) overall scores were analyzed. Results: A total of 198 (31.0%) subjects had an NT-proBNP ≤1,000 pg/ml at 90 days with no difference in achievement of NT-proBNP goal between the biomarker-guided and usual care arms. NT-proBNP ≤1,000 pg/ml by 90 days was associated with longer freedom from CV/HF hospitalization or all-cause mortality (p < 0.001 for both) and lower adjusted hazard of subsequent HF hospitalization/CV death (hazard ratio: 0.26; 95% confidence interval: 0.15 to 0.46; p < 0.001) and all-cause mortality (hazard ratio: 0.34; 95% confidence interval: 0.15 to 0.77; p = 0.009). Regardless of elevated baseline concentration, an NT-proBNP ≤1,000 pg/ml at 90 days was associated with better outcomes and significantly better KCCQ overall scores (p = 0.02). Conclusions: Patients with heart failure with reduced ejection fraction whose NT-proBNP levels decreased to ≤1,000 pg/ml during GDMT had better outcomes. These findings may help to understand the results of the GUIDE-IT trial. (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment [GUIDE-IT]; NCT01685840)

Original languageEnglish (US)
Pages (from-to)1205-1217
Number of pages13
JournalJournal of the American College of Cardiology
Volume74
Issue number9
DOIs
StatePublished - Sep 3 2019

Fingerprint

Natriuretic Peptides
Heart Failure
Hospitalization
Biomarkers
Guidelines
Therapeutics
Cardiomyopathies
Mortality
Confidence Intervals
pro-brain natriuretic peptide (1-76)
Random Allocation

Keywords

  • heart failure
  • natriuretic peptides
  • outcomes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Januzzi, J. L., Ahmad, T., Mulder, H., Coles, A., Anstrom, K. J., Adams, K. F., ... O'Connor, C. M. (2019). Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 74(9), 1205-1217. https://doi.org/10.1016/j.jacc.2019.06.055

Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. / Januzzi, James L.; Ahmad, Tariq; Mulder, Hillary; Coles, Adrian; Anstrom, Kevin J.; Adams, Kirkwood F.; Ezekowitz, Justin A.; Fiuzat, Mona; Houston-Miller, Nancy; Mark, Daniel B.; Pina, Ileana L.; Passmore, Gayle; Whellan, David J.; Cooper, Lawton S.; Leifer, Eric S.; Desvigne-Nickens, Patrice; Felker, G. Michael; O'Connor, Christopher M.

In: Journal of the American College of Cardiology, Vol. 74, No. 9, 03.09.2019, p. 1205-1217.

Research output: Contribution to journalArticle

Januzzi, JL, Ahmad, T, Mulder, H, Coles, A, Anstrom, KJ, Adams, KF, Ezekowitz, JA, Fiuzat, M, Houston-Miller, N, Mark, DB, Pina, IL, Passmore, G, Whellan, DJ, Cooper, LS, Leifer, ES, Desvigne-Nickens, P, Felker, GM & O'Connor, CM 2019, 'Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction', Journal of the American College of Cardiology, vol. 74, no. 9, pp. 1205-1217. https://doi.org/10.1016/j.jacc.2019.06.055
Januzzi, James L. ; Ahmad, Tariq ; Mulder, Hillary ; Coles, Adrian ; Anstrom, Kevin J. ; Adams, Kirkwood F. ; Ezekowitz, Justin A. ; Fiuzat, Mona ; Houston-Miller, Nancy ; Mark, Daniel B. ; Pina, Ileana L. ; Passmore, Gayle ; Whellan, David J. ; Cooper, Lawton S. ; Leifer, Eric S. ; Desvigne-Nickens, Patrice ; Felker, G. Michael ; O'Connor, Christopher M. / Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. In: Journal of the American College of Cardiology. 2019 ; Vol. 74, No. 9. pp. 1205-1217.
@article{d279486367ed43ecb50908092cf3deca,
title = "Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction",
abstract = "Background: The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial demonstrated that a strategy to “guide” application of guideline-directed medical therapy (GDMT) by reducing amino-terminal pro–B-type natriuretic peptide (NT-proBNP) was not superior to GDMT alone. Objectives: The purpose of this study was to examine the prognostic meaning of NT-proBNP changes following heart failure (HF) therapy intensification relative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT trial. Methods: A total of 638 study participants were included who were alive and had available NT-proBNP results 90 days after randomization. Rates of subsequent cardiovascular (CV) death/HF hospitalization or all-cause mortality during follow-up and Kansas City Cardiomyopathy Questionnaire (KCCQ) overall scores were analyzed. Results: A total of 198 (31.0{\%}) subjects had an NT-proBNP ≤1,000 pg/ml at 90 days with no difference in achievement of NT-proBNP goal between the biomarker-guided and usual care arms. NT-proBNP ≤1,000 pg/ml by 90 days was associated with longer freedom from CV/HF hospitalization or all-cause mortality (p < 0.001 for both) and lower adjusted hazard of subsequent HF hospitalization/CV death (hazard ratio: 0.26; 95{\%} confidence interval: 0.15 to 0.46; p < 0.001) and all-cause mortality (hazard ratio: 0.34; 95{\%} confidence interval: 0.15 to 0.77; p = 0.009). Regardless of elevated baseline concentration, an NT-proBNP ≤1,000 pg/ml at 90 days was associated with better outcomes and significantly better KCCQ overall scores (p = 0.02). Conclusions: Patients with heart failure with reduced ejection fraction whose NT-proBNP levels decreased to ≤1,000 pg/ml during GDMT had better outcomes. These findings may help to understand the results of the GUIDE-IT trial. (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment [GUIDE-IT]; NCT01685840)",
keywords = "heart failure, natriuretic peptides, outcomes",
author = "Januzzi, {James L.} and Tariq Ahmad and Hillary Mulder and Adrian Coles and Anstrom, {Kevin J.} and Adams, {Kirkwood F.} and Ezekowitz, {Justin A.} and Mona Fiuzat and Nancy Houston-Miller and Mark, {Daniel B.} and Pina, {Ileana L.} and Gayle Passmore and Whellan, {David J.} and Cooper, {Lawton S.} and Leifer, {Eric S.} and Patrice Desvigne-Nickens and Felker, {G. Michael} and O'Connor, {Christopher M.}",
year = "2019",
month = "9",
day = "3",
doi = "10.1016/j.jacc.2019.06.055",
language = "English (US)",
volume = "74",
pages = "1205--1217",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction

AU - Januzzi, James L.

AU - Ahmad, Tariq

AU - Mulder, Hillary

AU - Coles, Adrian

AU - Anstrom, Kevin J.

AU - Adams, Kirkwood F.

AU - Ezekowitz, Justin A.

AU - Fiuzat, Mona

AU - Houston-Miller, Nancy

AU - Mark, Daniel B.

AU - Pina, Ileana L.

AU - Passmore, Gayle

AU - Whellan, David J.

AU - Cooper, Lawton S.

AU - Leifer, Eric S.

AU - Desvigne-Nickens, Patrice

AU - Felker, G. Michael

AU - O'Connor, Christopher M.

PY - 2019/9/3

Y1 - 2019/9/3

N2 - Background: The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial demonstrated that a strategy to “guide” application of guideline-directed medical therapy (GDMT) by reducing amino-terminal pro–B-type natriuretic peptide (NT-proBNP) was not superior to GDMT alone. Objectives: The purpose of this study was to examine the prognostic meaning of NT-proBNP changes following heart failure (HF) therapy intensification relative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT trial. Methods: A total of 638 study participants were included who were alive and had available NT-proBNP results 90 days after randomization. Rates of subsequent cardiovascular (CV) death/HF hospitalization or all-cause mortality during follow-up and Kansas City Cardiomyopathy Questionnaire (KCCQ) overall scores were analyzed. Results: A total of 198 (31.0%) subjects had an NT-proBNP ≤1,000 pg/ml at 90 days with no difference in achievement of NT-proBNP goal between the biomarker-guided and usual care arms. NT-proBNP ≤1,000 pg/ml by 90 days was associated with longer freedom from CV/HF hospitalization or all-cause mortality (p < 0.001 for both) and lower adjusted hazard of subsequent HF hospitalization/CV death (hazard ratio: 0.26; 95% confidence interval: 0.15 to 0.46; p < 0.001) and all-cause mortality (hazard ratio: 0.34; 95% confidence interval: 0.15 to 0.77; p = 0.009). Regardless of elevated baseline concentration, an NT-proBNP ≤1,000 pg/ml at 90 days was associated with better outcomes and significantly better KCCQ overall scores (p = 0.02). Conclusions: Patients with heart failure with reduced ejection fraction whose NT-proBNP levels decreased to ≤1,000 pg/ml during GDMT had better outcomes. These findings may help to understand the results of the GUIDE-IT trial. (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment [GUIDE-IT]; NCT01685840)

AB - Background: The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial demonstrated that a strategy to “guide” application of guideline-directed medical therapy (GDMT) by reducing amino-terminal pro–B-type natriuretic peptide (NT-proBNP) was not superior to GDMT alone. Objectives: The purpose of this study was to examine the prognostic meaning of NT-proBNP changes following heart failure (HF) therapy intensification relative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT trial. Methods: A total of 638 study participants were included who were alive and had available NT-proBNP results 90 days after randomization. Rates of subsequent cardiovascular (CV) death/HF hospitalization or all-cause mortality during follow-up and Kansas City Cardiomyopathy Questionnaire (KCCQ) overall scores were analyzed. Results: A total of 198 (31.0%) subjects had an NT-proBNP ≤1,000 pg/ml at 90 days with no difference in achievement of NT-proBNP goal between the biomarker-guided and usual care arms. NT-proBNP ≤1,000 pg/ml by 90 days was associated with longer freedom from CV/HF hospitalization or all-cause mortality (p < 0.001 for both) and lower adjusted hazard of subsequent HF hospitalization/CV death (hazard ratio: 0.26; 95% confidence interval: 0.15 to 0.46; p < 0.001) and all-cause mortality (hazard ratio: 0.34; 95% confidence interval: 0.15 to 0.77; p = 0.009). Regardless of elevated baseline concentration, an NT-proBNP ≤1,000 pg/ml at 90 days was associated with better outcomes and significantly better KCCQ overall scores (p = 0.02). Conclusions: Patients with heart failure with reduced ejection fraction whose NT-proBNP levels decreased to ≤1,000 pg/ml during GDMT had better outcomes. These findings may help to understand the results of the GUIDE-IT trial. (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment [GUIDE-IT]; NCT01685840)

KW - heart failure

KW - natriuretic peptides

KW - outcomes

UR - http://www.scopus.com/inward/record.url?scp=85070883197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070883197&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2019.06.055

DO - 10.1016/j.jacc.2019.06.055

M3 - Article

C2 - 31466618

AN - SCOPUS:85070883197

VL - 74

SP - 1205

EP - 1217

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 9

ER -